Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Calidi Biotherapeutics ( (CLDI) ) has issued an announcement.
On May 14, 2026, Calidi Biotherapeutics reported first-quarter 2026 results and highlighted new preclinical data underscoring the potential of its RedTail-based candidates CLD-401 and CLD-501 to reshape immune activity in the tumor microenvironment. The company also showcased platform advances at major oncology and gene therapy meetings, secured an AI-driven regulatory collaboration, and reduced general and administrative expenses by $1 million year over year, while narrowing its net loss and modestly increasing its cash position.
In April 2026, Calidi presented AACR data showing CLD-401 recruited multiple immune cell types and CLD-501 enabled localized T-cell engager and IL-15 SA expression, which could address limitations of existing immunotherapies. Additional presentations at ASGCT and IOVC highlighted CLD-401’s IL15-SA expression profile and a RedTail virus design that may evade immune clearance, reinforcing Calidi’s bid to position RedTail as a differentiated systemic virotherapy platform for solid tumors.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.
The score is primarily constrained by weak financial performance (minimal revenue, large losses, and heavy cash burn) and bearish technicals (price below key moving averages and negative MACD). Balance-sheet improvement and ongoing pipeline progress provide partial support, but dilution and continued financing needs remain meaningful risks.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics Inc., headquartered in San Diego, is a biotechnology company developing targeted genetic medicines using its proprietary RedTail platform, an engineered enveloped oncolytic virus for systemic delivery to metastatic tumor sites. Lead candidate CLD-401 is in IND-enabling studies for non-small cell lung cancer, head and neck cancer and other tumors with high unmet need, and the company is expanding its pipeline with in situ T-cell engager approaches for solid tumors.
Average Trading Volume: 3,846,994
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.02M
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.